Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc. - Seite 3

Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company’s filings with the SEC. The Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) may be obtained by contacting the Company, through the Company’s website at https://www.reatapharma.com or through the SEC’s Electronic Data Gathering and Analysis Retrieval System at https://www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230921976967/en/

The Reata Pharmaceuticals Registered (A) Stock at the time of publication of the news with a raise of +0,04 % to 172,3USD on Nasdaq stock exchange (21. September 2023, 15:54 Uhr).